Loading…
Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy
BACKGROUND AND AIMS: The standard palliative chemotherapy for pancreatic ductal adenocarcinoma (PDAC) is gemcitabine-based chemotherapy; however, PDAC still presents a major therapeutic challenge. The aims of this study were to investigate the expression pattern of genes involved in gemcitabine sens...
Saved in:
Published in: | Neoplasia (New York, N.Y.) N.Y.), 2010-10, Vol.12 (10), p.807,IN7-817,IN8 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c527t-c26a128fd6598b7a315ba3170f902f16b4e25afd1d2719cd48348c3094e388723 |
---|---|
cites | cdi_FETCH-LOGICAL-c527t-c26a128fd6598b7a315ba3170f902f16b4e25afd1d2719cd48348c3094e388723 |
container_end_page | 817,IN8 |
container_issue | 10 |
container_start_page | 807,IN7 |
container_title | Neoplasia (New York, N.Y.) |
container_volume | 12 |
creator | Fujita, Hayato Ohuchida, Kenoki Mizumoto, Kazuhiro Itaba, Soichi Ito, Tetsuhide Nakata, Kohei Yu, Jun Kayashima, Tadashi Souzaki, Ryota Tajiri, Tatsuro Manabe, Tatsuya Ohtsuka, Takao Tanaka, Masao |
description | BACKGROUND AND AIMS: The standard palliative chemotherapy for pancreatic ductal adenocarcinoma (PDAC) is gemcitabine-based chemotherapy; however, PDAC still presents a major therapeutic challenge. The aims of this study were to investigate the expression pattern of genes involved in gemcitabine sensitivity in resected PDAC tissues and to determine correlations of gene expression with treatment outcome. MATERIALS AND METHODS: We obtained formalin-fixed paraffin-embedded (FFPE) tissue samples from 70 patients with PDAC. Of the 70 patients, 40 received gemcitabine-based adjuvant chemotherapy (AC). We measured hENT1, dCK, CDA, RRM1, and RRM2 messenger RNA (mRNA) levels by quantitative real-time reverse transcription-polymerase chain reaction and determined the combined score (GEM score), based on the expression levels of hENT1, dCK, RRM1, and RRM2, to investigate the association with survival time. By determining the expression levels of these genes in endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) cytologic specimens, we investigated the feasibility of individualized chemotherapy. RESULTS: High dCK (P = .0067), low RRM2 (P = .003), and high GEM score (P = .0003) groups had a significantly longer disease-free survival in the gemcitabine-treated group. A low GEM score ( |
doi_str_mv | 10.1593/neo.10458 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2bdc4f289f4c4fdbaae78af681f3c131</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S147655861080048X</els_id><doaj_id>oai_doaj_org_article_2bdc4f289f4c4fdbaae78af681f3c131</doaj_id><sourcerecordid>923205409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-c26a128fd6598b7a315ba3170f902f16b4e25afd1d2719cd48348c3094e388723</originalsourceid><addsrcrecordid>eNptkU1v1DAQhiMEoqVw4A8g3xCHFH8ksX0sq7JUWtQe4GxN7DH1ksSL7V1Rfj2mWyoOXGZG1uPXGj9N85rRc9Zr8X7BeM5o16snzSnr5ND2vRqe_jOfNC9y3lLKBibl8-aEU82lYPq0-bXGBcnlz13CnENcyAYPOGUCmdwkdMGWcEDyGdJ3TJlET673xcYZSVjIDSw2IZRgyaqOmAj4UusaZxsKjGHB9gNkdOTCbfcHWApZ3eIcyy0m2N29bJ55mDK-euhnzdePl19Wn9rN9fpqdbFpbc9laS0fgHHl3dBrNUoQrB9rkdRryj0bxg55D94xxyXT1nVKdMoKqjsUSkkuzpqrY66LsDW7FGZIdyZCMPcHMX0zkOoSExo-Ott5rrTvancjAEoFflDMC8sEq1lvj1m7FH_sMRczh2xxmqA62GejueC076iu5LsjaVPMOaF_fJlR88eaqTfMvbXKvnlI3Y8zukfyr6YKiCNQ1eAhYDLZBqxf7kJCW-oi4T-xvwHe4qT-</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>923205409</pqid></control><display><type>article</type><title>Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy</title><source>ScienceDirect</source><source>Open Access: PubMed Central</source><creator>Fujita, Hayato ; Ohuchida, Kenoki ; Mizumoto, Kazuhiro ; Itaba, Soichi ; Ito, Tetsuhide ; Nakata, Kohei ; Yu, Jun ; Kayashima, Tadashi ; Souzaki, Ryota ; Tajiri, Tatsuro ; Manabe, Tatsuya ; Ohtsuka, Takao ; Tanaka, Masao</creator><creatorcontrib>Fujita, Hayato ; Ohuchida, Kenoki ; Mizumoto, Kazuhiro ; Itaba, Soichi ; Ito, Tetsuhide ; Nakata, Kohei ; Yu, Jun ; Kayashima, Tadashi ; Souzaki, Ryota ; Tajiri, Tatsuro ; Manabe, Tatsuya ; Ohtsuka, Takao ; Tanaka, Masao</creatorcontrib><description>BACKGROUND AND AIMS: The standard palliative chemotherapy for pancreatic ductal adenocarcinoma (PDAC) is gemcitabine-based chemotherapy; however, PDAC still presents a major therapeutic challenge. The aims of this study were to investigate the expression pattern of genes involved in gemcitabine sensitivity in resected PDAC tissues and to determine correlations of gene expression with treatment outcome. MATERIALS AND METHODS: We obtained formalin-fixed paraffin-embedded (FFPE) tissue samples from 70 patients with PDAC. Of the 70 patients, 40 received gemcitabine-based adjuvant chemotherapy (AC). We measured hENT1, dCK, CDA, RRM1, and RRM2 messenger RNA (mRNA) levels by quantitative real-time reverse transcription-polymerase chain reaction and determined the combined score (GEM score), based on the expression levels of hENT1, dCK, RRM1, and RRM2, to investigate the association with survival time. By determining the expression levels of these genes in endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) cytologic specimens, we investigated the feasibility of individualized chemotherapy. RESULTS: High dCK (P = .0067), low RRM2 (P = .003), and high GEM score (P = .0003) groups had a significantly longer disease-free survival in the gemcitabine-treated group. A low GEM score (<2) was an independent predictive marker for poor outcome to gemcitabine-based AC as shown by multivariate analysis (P = .0081). Altered expression levels of these genes were distinguishable in microdissected neoplastic cells from EUS-FNA cytologic specimens. CONCLUSIONS: Quantitative analyses of hENT1, dCK, RRM1, and RRM2 mRNA levels using FFPE tissue samples and microdissected neoplastic cells from EUS-FNA cytologic specimens may be useful in predicting the gemcitabine sensitivity of patients with PDAC.</description><identifier>ISSN: 1476-5586</identifier><identifier>ISSN: 1522-8002</identifier><identifier>EISSN: 1476-5586</identifier><identifier>EISSN: 1522-8002</identifier><identifier>DOI: 10.1593/neo.10458</identifier><identifier>PMID: 20927319</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - genetics ; Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic - therapeutic use ; Biomarkers, Tumor - genetics ; Biopsy, Fine-Needle ; Carcinoma, Adenosquamous - drug therapy ; Carcinoma, Adenosquamous - genetics ; Cytidine Deaminase - genetics ; Cytidine Deaminase - metabolism ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Deoxycytidine Kinase - genetics ; Deoxycytidine Kinase - metabolism ; Equilibrative Nucleoside Transporter 1 - genetics ; Equilibrative Nucleoside Transporter 1 - metabolism ; Feasibility Studies ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic - physiology ; Humans ; Immunoenzyme Techniques ; Male ; Middle Aged ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - genetics ; Reverse Transcriptase Polymerase Chain Reaction ; Ribonucleoside Diphosphate Reductase - genetics ; Ribonucleoside Diphosphate Reductase - metabolism ; RNA, Messenger - genetics ; Survival Rate ; Treatment Outcome ; Tumor Cells, Cultured ; Tumor Suppressor Proteins - genetics ; Tumor Suppressor Proteins - metabolism</subject><ispartof>Neoplasia (New York, N.Y.), 2010-10, Vol.12 (10), p.807,IN7-817,IN8</ispartof><rights>2010 Neoplasia Press, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-c26a128fd6598b7a315ba3170f902f16b4e25afd1d2719cd48348c3094e388723</citedby><cites>FETCH-LOGICAL-c527t-c26a128fd6598b7a315ba3170f902f16b4e25afd1d2719cd48348c3094e388723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S147655861080048X$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20927319$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fujita, Hayato</creatorcontrib><creatorcontrib>Ohuchida, Kenoki</creatorcontrib><creatorcontrib>Mizumoto, Kazuhiro</creatorcontrib><creatorcontrib>Itaba, Soichi</creatorcontrib><creatorcontrib>Ito, Tetsuhide</creatorcontrib><creatorcontrib>Nakata, Kohei</creatorcontrib><creatorcontrib>Yu, Jun</creatorcontrib><creatorcontrib>Kayashima, Tadashi</creatorcontrib><creatorcontrib>Souzaki, Ryota</creatorcontrib><creatorcontrib>Tajiri, Tatsuro</creatorcontrib><creatorcontrib>Manabe, Tatsuya</creatorcontrib><creatorcontrib>Ohtsuka, Takao</creatorcontrib><creatorcontrib>Tanaka, Masao</creatorcontrib><title>Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy</title><title>Neoplasia (New York, N.Y.)</title><addtitle>Neoplasia</addtitle><description>BACKGROUND AND AIMS: The standard palliative chemotherapy for pancreatic ductal adenocarcinoma (PDAC) is gemcitabine-based chemotherapy; however, PDAC still presents a major therapeutic challenge. The aims of this study were to investigate the expression pattern of genes involved in gemcitabine sensitivity in resected PDAC tissues and to determine correlations of gene expression with treatment outcome. MATERIALS AND METHODS: We obtained formalin-fixed paraffin-embedded (FFPE) tissue samples from 70 patients with PDAC. Of the 70 patients, 40 received gemcitabine-based adjuvant chemotherapy (AC). We measured hENT1, dCK, CDA, RRM1, and RRM2 messenger RNA (mRNA) levels by quantitative real-time reverse transcription-polymerase chain reaction and determined the combined score (GEM score), based on the expression levels of hENT1, dCK, RRM1, and RRM2, to investigate the association with survival time. By determining the expression levels of these genes in endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) cytologic specimens, we investigated the feasibility of individualized chemotherapy. RESULTS: High dCK (P = .0067), low RRM2 (P = .003), and high GEM score (P = .0003) groups had a significantly longer disease-free survival in the gemcitabine-treated group. A low GEM score (<2) was an independent predictive marker for poor outcome to gemcitabine-based AC as shown by multivariate analysis (P = .0081). Altered expression levels of these genes were distinguishable in microdissected neoplastic cells from EUS-FNA cytologic specimens. CONCLUSIONS: Quantitative analyses of hENT1, dCK, RRM1, and RRM2 mRNA levels using FFPE tissue samples and microdissected neoplastic cells from EUS-FNA cytologic specimens may be useful in predicting the gemcitabine sensitivity of patients with PDAC.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - genetics</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biopsy, Fine-Needle</subject><subject>Carcinoma, Adenosquamous - drug therapy</subject><subject>Carcinoma, Adenosquamous - genetics</subject><subject>Cytidine Deaminase - genetics</subject><subject>Cytidine Deaminase - metabolism</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Deoxycytidine Kinase - genetics</subject><subject>Deoxycytidine Kinase - metabolism</subject><subject>Equilibrative Nucleoside Transporter 1 - genetics</subject><subject>Equilibrative Nucleoside Transporter 1 - metabolism</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Gene Expression Profiling</subject><subject>Gene Expression Regulation, Neoplastic - physiology</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - genetics</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Ribonucleoside Diphosphate Reductase - genetics</subject><subject>Ribonucleoside Diphosphate Reductase - metabolism</subject><subject>RNA, Messenger - genetics</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Tumor Cells, Cultured</subject><subject>Tumor Suppressor Proteins - genetics</subject><subject>Tumor Suppressor Proteins - metabolism</subject><issn>1476-5586</issn><issn>1522-8002</issn><issn>1476-5586</issn><issn>1522-8002</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptkU1v1DAQhiMEoqVw4A8g3xCHFH8ksX0sq7JUWtQe4GxN7DH1ksSL7V1Rfj2mWyoOXGZG1uPXGj9N85rRc9Zr8X7BeM5o16snzSnr5ND2vRqe_jOfNC9y3lLKBibl8-aEU82lYPq0-bXGBcnlz13CnENcyAYPOGUCmdwkdMGWcEDyGdJ3TJlET673xcYZSVjIDSw2IZRgyaqOmAj4UusaZxsKjGHB9gNkdOTCbfcHWApZ3eIcyy0m2N29bJ55mDK-euhnzdePl19Wn9rN9fpqdbFpbc9laS0fgHHl3dBrNUoQrB9rkdRryj0bxg55D94xxyXT1nVKdMoKqjsUSkkuzpqrY66LsDW7FGZIdyZCMPcHMX0zkOoSExo-Ott5rrTvancjAEoFflDMC8sEq1lvj1m7FH_sMRczh2xxmqA62GejueC076iu5LsjaVPMOaF_fJlR88eaqTfMvbXKvnlI3Y8zukfyr6YKiCNQ1eAhYDLZBqxf7kJCW-oi4T-xvwHe4qT-</recordid><startdate>20101001</startdate><enddate>20101001</enddate><creator>Fujita, Hayato</creator><creator>Ohuchida, Kenoki</creator><creator>Mizumoto, Kazuhiro</creator><creator>Itaba, Soichi</creator><creator>Ito, Tetsuhide</creator><creator>Nakata, Kohei</creator><creator>Yu, Jun</creator><creator>Kayashima, Tadashi</creator><creator>Souzaki, Ryota</creator><creator>Tajiri, Tatsuro</creator><creator>Manabe, Tatsuya</creator><creator>Ohtsuka, Takao</creator><creator>Tanaka, Masao</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>DOA</scope></search><sort><creationdate>20101001</creationdate><title>Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy</title><author>Fujita, Hayato ; Ohuchida, Kenoki ; Mizumoto, Kazuhiro ; Itaba, Soichi ; Ito, Tetsuhide ; Nakata, Kohei ; Yu, Jun ; Kayashima, Tadashi ; Souzaki, Ryota ; Tajiri, Tatsuro ; Manabe, Tatsuya ; Ohtsuka, Takao ; Tanaka, Masao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-c26a128fd6598b7a315ba3170f902f16b4e25afd1d2719cd48348c3094e388723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - genetics</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biopsy, Fine-Needle</topic><topic>Carcinoma, Adenosquamous - drug therapy</topic><topic>Carcinoma, Adenosquamous - genetics</topic><topic>Cytidine Deaminase - genetics</topic><topic>Cytidine Deaminase - metabolism</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Deoxycytidine Kinase - genetics</topic><topic>Deoxycytidine Kinase - metabolism</topic><topic>Equilibrative Nucleoside Transporter 1 - genetics</topic><topic>Equilibrative Nucleoside Transporter 1 - metabolism</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Gene Expression Profiling</topic><topic>Gene Expression Regulation, Neoplastic - physiology</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - genetics</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Ribonucleoside Diphosphate Reductase - genetics</topic><topic>Ribonucleoside Diphosphate Reductase - metabolism</topic><topic>RNA, Messenger - genetics</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Tumor Cells, Cultured</topic><topic>Tumor Suppressor Proteins - genetics</topic><topic>Tumor Suppressor Proteins - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fujita, Hayato</creatorcontrib><creatorcontrib>Ohuchida, Kenoki</creatorcontrib><creatorcontrib>Mizumoto, Kazuhiro</creatorcontrib><creatorcontrib>Itaba, Soichi</creatorcontrib><creatorcontrib>Ito, Tetsuhide</creatorcontrib><creatorcontrib>Nakata, Kohei</creatorcontrib><creatorcontrib>Yu, Jun</creatorcontrib><creatorcontrib>Kayashima, Tadashi</creatorcontrib><creatorcontrib>Souzaki, Ryota</creatorcontrib><creatorcontrib>Tajiri, Tatsuro</creatorcontrib><creatorcontrib>Manabe, Tatsuya</creatorcontrib><creatorcontrib>Ohtsuka, Takao</creatorcontrib><creatorcontrib>Tanaka, Masao</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>DOAJÂ Directory of Open Access Journals</collection><jtitle>Neoplasia (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fujita, Hayato</au><au>Ohuchida, Kenoki</au><au>Mizumoto, Kazuhiro</au><au>Itaba, Soichi</au><au>Ito, Tetsuhide</au><au>Nakata, Kohei</au><au>Yu, Jun</au><au>Kayashima, Tadashi</au><au>Souzaki, Ryota</au><au>Tajiri, Tatsuro</au><au>Manabe, Tatsuya</au><au>Ohtsuka, Takao</au><au>Tanaka, Masao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy</atitle><jtitle>Neoplasia (New York, N.Y.)</jtitle><addtitle>Neoplasia</addtitle><date>2010-10-01</date><risdate>2010</risdate><volume>12</volume><issue>10</issue><spage>807,IN7</spage><epage>817,IN8</epage><pages>807,IN7-817,IN8</pages><issn>1476-5586</issn><issn>1522-8002</issn><eissn>1476-5586</eissn><eissn>1522-8002</eissn><abstract>BACKGROUND AND AIMS: The standard palliative chemotherapy for pancreatic ductal adenocarcinoma (PDAC) is gemcitabine-based chemotherapy; however, PDAC still presents a major therapeutic challenge. The aims of this study were to investigate the expression pattern of genes involved in gemcitabine sensitivity in resected PDAC tissues and to determine correlations of gene expression with treatment outcome. MATERIALS AND METHODS: We obtained formalin-fixed paraffin-embedded (FFPE) tissue samples from 70 patients with PDAC. Of the 70 patients, 40 received gemcitabine-based adjuvant chemotherapy (AC). We measured hENT1, dCK, CDA, RRM1, and RRM2 messenger RNA (mRNA) levels by quantitative real-time reverse transcription-polymerase chain reaction and determined the combined score (GEM score), based on the expression levels of hENT1, dCK, RRM1, and RRM2, to investigate the association with survival time. By determining the expression levels of these genes in endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) cytologic specimens, we investigated the feasibility of individualized chemotherapy. RESULTS: High dCK (P = .0067), low RRM2 (P = .003), and high GEM score (P = .0003) groups had a significantly longer disease-free survival in the gemcitabine-treated group. A low GEM score (<2) was an independent predictive marker for poor outcome to gemcitabine-based AC as shown by multivariate analysis (P = .0081). Altered expression levels of these genes were distinguishable in microdissected neoplastic cells from EUS-FNA cytologic specimens. CONCLUSIONS: Quantitative analyses of hENT1, dCK, RRM1, and RRM2 mRNA levels using FFPE tissue samples and microdissected neoplastic cells from EUS-FNA cytologic specimens may be useful in predicting the gemcitabine sensitivity of patients with PDAC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20927319</pmid><doi>10.1593/neo.10458</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1476-5586 |
ispartof | Neoplasia (New York, N.Y.), 2010-10, Vol.12 (10), p.807,IN7-817,IN8 |
issn | 1476-5586 1522-8002 1476-5586 1522-8002 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_2bdc4f289f4c4fdbaae78af681f3c131 |
source | ScienceDirect; Open Access: PubMed Central |
subjects | Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adult Aged Aged, 80 and over Antimetabolites, Antineoplastic - therapeutic use Biomarkers, Tumor - genetics Biopsy, Fine-Needle Carcinoma, Adenosquamous - drug therapy Carcinoma, Adenosquamous - genetics Cytidine Deaminase - genetics Cytidine Deaminase - metabolism Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Deoxycytidine Kinase - genetics Deoxycytidine Kinase - metabolism Equilibrative Nucleoside Transporter 1 - genetics Equilibrative Nucleoside Transporter 1 - metabolism Feasibility Studies Female Gene Expression Profiling Gene Expression Regulation, Neoplastic - physiology Humans Immunoenzyme Techniques Male Middle Aged Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Reverse Transcriptase Polymerase Chain Reaction Ribonucleoside Diphosphate Reductase - genetics Ribonucleoside Diphosphate Reductase - metabolism RNA, Messenger - genetics Survival Rate Treatment Outcome Tumor Cells, Cultured Tumor Suppressor Proteins - genetics Tumor Suppressor Proteins - metabolism |
title | Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T09%3A48%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gene%20Expression%20Levels%20as%20Predictive%20Markers%20of%20Outcome%20in%20Pancreatic%20Cancer%20after%20Gemcitabine-Based%20Adjuvant%20Chemotherapy&rft.jtitle=Neoplasia%20(New%20York,%20N.Y.)&rft.au=Fujita,%20Hayato&rft.date=2010-10-01&rft.volume=12&rft.issue=10&rft.spage=807,IN7&rft.epage=817,IN8&rft.pages=807,IN7-817,IN8&rft.issn=1476-5586&rft.eissn=1476-5586&rft_id=info:doi/10.1593/neo.10458&rft_dat=%3Cproquest_doaj_%3E923205409%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c527t-c26a128fd6598b7a315ba3170f902f16b4e25afd1d2719cd48348c3094e388723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=923205409&rft_id=info:pmid/20927319&rfr_iscdi=true |